Gianluca Moroncini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2576584/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Plateletâ€activating factor acetylhydrolase: A biomarker in Hymenoptera venom allergy?. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1032-1035.	5.7	5
2	Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 2022, 10, 163.	3.2	16
3	PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis. International Journal of Molecular Sciences, 2022, 23, 3904.	4.1	13
4	SARS-COV-2 Infection, Vaccination, and Immune-Mediated Diseases: Results of a Single-Center Retrospective Study. Frontiers in Immunology, 2022, 13, 859550.	4.8	9
5	A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases. Autoimmunity Reviews, 2022, 21, 103105.	5.8	17
6	Development of the optimal touchscreen interface for patients with scleroderma. Journal of Scleroderma and Related Disorders, 2021, 6, 170-177.	1.7	1
7	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. Annals of the Rheumatic Diseases, 2021, 80, 1040-1047.	0.9	24
8	Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease. Scandinavian Journal of Immunology, 2021, 94, e13101.	2.7	16
9	Putative functional pathogenic autoantibodies in systemic sclerosis. European Journal of Rheumatology, 2020, 7, 181-186.	0.6	8
10	History and Scientific Production of Clinica Medica and Clinica Ematologica in Ancona. , 2020, , 1-11.		0
11	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications, 2019, 10, 4955.	12.8	100
12	Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin. Journal of Visualized Experiments, 2019, , .	0.3	6
13	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews, 2019, 18, 93-106.	5.8	101
14	NADPH oxidase, oxidative stress and fibrosis in systemic sclerosis. Free Radical Biology and Medicine, 2018, 125, 90-97.	2.9	29
15	Agonistic antibodies in systemic sclerosis. Immunology Letters, 2018, 195, 83-87.	2.5	22
16	Biologics in Inflammatory Immune-mediated Systemic Diseases. Current Pharmaceutical Biotechnology, 2018, 18, 1008-1016.	1.6	17
17	Developments in the management of advanced soft-tissue sarcoma – olaratumab in context. OncoTargets and Therapy, 2018, Volume 11, 833-842.	2.0	13
18	Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. PLoS ONE, 2018, 13, e0196048.	2.5	34

#	Article	IF	CITATIONS
19	Mycophenolate mofetil-induced colitis in a patient with systemic sclerosis. BMJ Case Reports, 2018, 2018, bcr-2018-224829.	0.5	6
20	Analysis of <i>ATP8B4</i> F436L Missense Variant in a Large Systemic Sclerosis Cohort. Arthritis and Rheumatology, 2017, 69, 1337-1338.	5.6	9
21	Reply. Arthritis and Rheumatology, 2017, 69, 1703-1704.	5.6	Ο
22	Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro. Frontiers in Immunology, 2017, 8, 75.	4.8	25
23	Lack of interleukin-13 receptor α1 delays the loss of dopaminergic neurons during chronic stress. Journal of Neuroinflammation, 2017, 14, 88.	7.2	24
24	Characterization of binding and quantification of human autoantibodies to PDGFRα using a biosensor-based approach. Analytical Biochemistry, 2017, 528, 26-33.	2.4	12
25	Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile. Current Drug Safety, 2016, 11, 44-46.	0.6	0
26	Induction of Scleroderma Fibrosis in Skinâ€Humanized Mice by Administration of Antiâ^'Plateletâ€Derived Growth Factor Receptor Agonistic Autoantibodies. Arthritis and Rheumatology, 2016, 68, 2263-2273.	5.6	42
27	The Proinflammatory Cytokine Interleukin 18 Regulates Feeding by Acting on the Bed Nucleus of the Stria Terminalis. Journal of Neuroscience, 2016, 36, 5170-5180.	3.6	27
28	Brief Report: <i>IRF4</i> Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Crossâ€Disease Metaâ€Analysis of Genomeâ€Wide Association Studies. Arthritis and Rheumatology, 2016, 68, 2338-2344.	5.6	46
29	Influence of <i>TYK2</i> in systemic sclerosis susceptibility: a new <i>locus</i> in the IL-12 pathway. Annals of the Rheumatic Diseases, 2016, 75, 1521-1526.	0.9	41
30	Comment on â€~Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?'. Autoimmunity Reviews, 2016, 15, 202.	5.8	0
31	Regional Implantation of Autologous Adipose Tissue-Derived Cells Induces a Prompt Healing of Long-Lasting Indolent Digital Ulcers in Patients with Systemic Sclerosis. Cell Transplantation, 2015, 24, 2297-2305.	2.5	80
32	Reply to J. Magalon et al Cell Transplantation, 2015, 24, 2669-2670.	2.5	3
33	Epitope Specificity Determines Pathogenicity and Detectability of Anti–Plateletâ€Derived Growth Factor Receptor α Autoantibodies in Systemic Sclerosis. Arthritis and Rheumatology, 2015, 67, 1891-1903.	5.6	32
34	Monoacylglycerol Lipase Regulates Fever Response. PLoS ONE, 2015, 10, e0134437.	2.5	11
35	Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?. Autoimmunity Reviews, 2015, 14, 575-578.	5.8	31
36	A Reactive Oxygen Species–Mediated Loop Maintains Increased Expression of NADPH Oxidases 2 and 4 in Skin Fibroblasts From Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2015, 67, 1611-1622.	5.6	54

#	Article	IF	CITATIONS
37	Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. Clinical and Experimental Rheumatology, 2015, 33, S160-7.	0.8	12
38	Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Science Signaling, 2014, 7, ra84.	3.6	84
39	Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Research and Therapy, 2014, 16, R144.	3.5	88
40	Myocardial perfusion defects in scleroderma detected by contrast-enhanced cardiovascular magnetic resonance. Radiologia Medica, 2014, 119, 885-894.	7.7	23
41	Role of viral infections in the etiopathogenesis of systemic sclerosis. Clinical and Experimental Rheumatology, 2013, 31, 3-7.	0.8	12
42	Downregulation of GPR83 in the hypothalamic preoptic area reduces core body temperature and elevates circulating levels of adiponectin. Metabolism: Clinical and Experimental, 2012, 61, 1486-1493.	3.4	25
43	New Insights into the Role of Oxidative Stress in Scleroderma Fibrosis. Open Rheumatology Journal, 2012, 6, 87-95.	0.2	65
44	Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts. Fibrogenesis and Tissue Repair, 2011, 4, 8.	3.4	20
45	Detection of typical and atypical bovine spongiform encephalopathy and scrapie prion strains by prion protein motif-grafted antibodies. Journal of General Virology, 2009, 90, 1048-1053.	2.9	6
46	Autoantibodies against the plateletâ€derived growth factor receptor in scleroderma: Comment on the articles by Classen et al and Loizos et al. Arthritis and Rheumatism, 2009, 60, 3521-3522.	6.7	12
47	Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Seminars in Immunopathology, 2008, 30, 329-337.	6.1	58
48	Hypothalamic–pituitary–adrenal axis disregulation in PrPC-null mice. NeuroReport, 2008, 19, 1473-1477.	1.2	7
49	Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction. Cellular Oncology, 2008, 30, 473-82.	1.9	7
50	Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood, 2007, 110, 237-241.	1.4	212
51	Stimulatory autoantibodies to the PDGF receptor: A link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmunity Reviews, 2007, 7, 121-126.	5.8	33
52	Contributions of neuronal prion protein on sleep recovery and stress response following sleep deprivation. Brain Research, 2007, 1158, 71-80.	2.2	29
53	Pathogenic autoantibodies in systemic sclerosis. Current Opinion in Immunology, 2007, 19, 640-645.	5.5	44
54	Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody. Neurobiology of Disease, 2006, 23, 717-724.	4.4	22

#	Article	IF	CITATIONS
55	Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10404-10409.	7.1	105
56	Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs. Virology, 2001, 288, 29-35.	2.4	38